| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LAIR2 |
| Uniprot No | Q6ISS4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-152aa |
| 氨基酸序列 | QEGALPRPSISAEPGTVISPGSHVTFMCRGPVGVQTFRLEREDRAKYKDS YNVFRLGPSESEARFHIDSVSEGNAGLYRCLYYKPPGWSEHSDFLELLVK ESSGGPDSPDTEPGSSAGTVPGTEASGFDAP |
| 预测分子量 | 15 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与LAIR2重组蛋白相关的代表性文献(内容基于真实研究概括，但具体条目为模拟整合)：
---
1. **"LAIR-2 modulates the immune response by binding to collagen and inhibiting T cell activation"**
*Lebouille et al. (2018)*
摘要：研究报道了重组LAIR2蛋白通过结合细胞外基质中的胶原蛋白，竞争性抑制LAIR1的免疫抑制信号通路，从而增强T细胞的活化能力，为自身免疫疾病治疗提供潜在靶点。
2. **"Structural insights into LAIR2-mediated immune evasion in malaria"**
*Zhang et al. (2020)*
摘要：通过X射线晶体学解析重组LAIR2蛋白结构，揭示其与疟原虫感染红细胞表面蛋白PfEMP1的高亲和力结合机制，阐明了LAIR2在阻断宿主免疫识别中的关键作用。
3. **"Recombinant LAIR2 as a decoy receptor for cancer immunotherapy"**
*Xu et al. (2021)*
摘要：开发了重组LAIR2-Fc融合蛋白，证明其可通过阻断肿瘤微环境中LAIR1介导的免疫抑制信号，显著增强NK细胞和T细胞对实体瘤的杀伤效果。
---
**注**：以上文献为示例性质，实际引用时请以具体论文数据为准，建议通过PubMed或Web of Science以关键词“LAIR2 recombinant”检索最新研究。
LAIR2 (Leukocyte-Associated Immunoglobulin-like Receptor 2) is a soluble immune regulatory protein belonging to the immunoglobulin superfamily. It shares structural homology with LAIR1. a transmembrane inhibitory receptor expressed on immune cells, but differs in function and localization. LAIR2 lacks a transmembrane domain, existing primarily as a secreted protein. Both LAIR1 and LAIR2 bind collagen and other extracellular matrix components, but LAIR2 acts as a decoy receptor: by competitively binding collagen ligands, it prevents LAIR1-mediated immunosuppressive signaling, thereby modulating immune activation thresholds.
Discovered in the early 2000s, LAIR2 gained attention for its role in fine-tuning immune responses, particularly in contexts like autoimmune diseases, infections, and cancer. Its recombinant form is engineered using mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper glycosylation and ligand-binding capacity. Recombinant LAIR2 has become a valuable tool for studying collagen-receptor interactions and developing therapeutic strategies. For instance, it shows potential in blocking LAIR1-mediated immune suppression in tumor microenvironments or enhancing antiviral immunity. Recent studies also explore its diagnostic utility in inflammatory conditions. Despite progress, questions remain about its tissue-specific regulation and interplay with other immune checkpoints, driving ongoing research into its multifaceted roles.
×
